Tweetorial: A Rationale for Treating CKD with Combination Therapy
Tweetorial: A Rationale for Treating CKD with Combination Therapy is organized by CME Institute of Physicians Postgraduate Press, Inc. (PPP).
Activity opens: 02/02/2023
Activity expires: 02/29/2024
Overview:
Clinicians have a number of therapeutic agents to choose from when treating T2D at risk of CKD. However, it's important to know how to sequence these therapies in real-world practice.
Program Description:
One in 10 Americans have type 2 diabetes (T2D), and 40% of patients with T2D have chronic kidney disease (CKD), which significantly increases the risk for cardiovascular disease in this patient population. In today’s treatment landscape for the reduction of renal and cardiovascular risk in patients with T2D at risk for progressive kidney disease, clinicians have a number of therapeutic agents to choose from. Those include sodium-glucose Cotransporter 2 (SGLT2) inhibitors, acetyl-CoA Carboxylase (ACC) inhibitors, Glucagon-like peptide-1 (GLP-1) receptor agonists, and mineralocorticoid receptor antagonists (MRAs). The latest drug to join the armamentarium is finerenone, an MRA which has been shown to reduce the risk of sustained eGFR decline, end stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with CKD. However, clinicians have been slow to implement guidelines in screening for CKD in patients with T2D, and clinicians need to know when and how to sequence these therapies in real-world practice. In this webinar Drs Erin Michos, MD, MHS, associate director of preventive cardiology at Johns Hopkins University School of Medicine, and Joel Topf, MD, FACP, assistant clinical professor of medicine at Oakland University, William Beaumont School of Medicine, discuss guideline-based recommendations for screening to evaluate CKD risk in patients with T2D, as well as real-world use of therapies that protect patients from CKD progression, including combination therapy with MRAs and other renoprotective agents, such as SGLT2 inhibitors. Finally, the two experts weigh in on three patient cases as a way of translating this knowledge into real-world practice.
Learning Objective
After completing this educational activity, you should be able to:
• Summarize the rationale and best practices for combination therapy with mineralocorticoid receptor antagonists and other renoprotective agents, such as SGLT2 inhibitors